Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
STAT2d
Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...
BioSpace2d
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
Lilly Expands Digital Health Site to Include Alzheimer’s Disease
Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, ...
Fierce Pharma2d
Eli Lilly's Alzheimer's contender Kisunla gets thumbs down from EU regulators over safety concerns
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
Explore more
Eli Lilly to seek re-examination by CHMP of opinion to not recommend donanemab
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...
Comisión europea sugiere no aprobar comercialización de fármaco de Lilly contra Alzheimer
Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...